Loading…
SPIRIVA RESPIMAT is a brand name for Tiotropium, supplied as a solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
, ipratropium) or to any component of this product (see DOSAGE FORMS, COMPOSITION AND PACKAGING). WARNINGS AND PRECAUTIONS General Not for Acute Use SPIRIVA RESPIMAT (tiotropium bromide monohydrate), as a once daily maintenance bronchodilator, should not be used for the initial treatment of acute episodes of bronchospasm or for the relief of acute symptoms.
In the event of an acute attack, a rapid-acting beta-2 agonist should be used. , four times a day) should be instructed to discontinue the regular use of these drugs. , short-acting beta-agonist) for treatment of COPD symptoms that occur acutely, despite regular once-daily use of SPIRIVA RESPIMAT.
SPIRIVA RESPIMAT should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition. If SPIRIVA RESPIMAT no longer controls the symptoms of bronchoconstriction, or the patient’s inhaled, short-acting beta2-agonist becomes less effective or the patient needs more inhalation of a short-acting bronchodilator than usual, these may be markers of deterioration of disease.
In this setting, a re-evaluation of the patient and the COPD treatment regimen should be undertaken at once. Increasing the daily dosage of SPIRIVA RESPIMAT beyond the recommended dose is not appropriate in this situation. Not for First Line Use in Asthma SPIRIVA RESPIMAT should not be used as a first-line treatment or monotherapy for asthma.
e. inhaled corticosteroid and long-acting beta-agonist), after the introduction of SPIRIVA RESPIMAT, even when their symptoms improve. Spiriva® Respimat® Product Monograph Page 5 of 41 Excessive Use SPIRIVA RESPIMAT should not be used more frequently than once daily or at higher doses than recommended.
g. ipratropium, tiotropium, glycopyrronium, aclidinium, umeclidinium), as an overdose may result. Effects on Ability to Drive or Use Machines No studies on the effects on the ability to drive and use machines have been performed. The occurrence of dizziness or blurred vision may influence the ability to drive and use machinery.
Anticholinergic Effects Like other anticholinergic drugs, SPIRIVA RESPIMAT should be used with caution in patients with narrow-angle glaucoma or urinary retention. Worsening of Narrow-Angle Glaucoma SPIRIVA RESPIMAT should be used with caution in patients with narrow-angle glaucoma.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Tiotropium in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Patients should be cautioned to avoid getting the mist into their eyes. They should be advised that this may result in precipitation or worsening of narrow-angle glaucoma. , eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema).
Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop. Miotic drops alone are not considered to be effective treatment. Worsening of Urinary Retention SPIRIVA RESPIMAT should be used with caution in patients with urinary retention.
, difficulty passing urine, painful urination). Instruct patients to consult a physician immediately should any of these signs or symptoms develop. g. atrial fibrillation and tachycardia), may be seen after the administration of muscarinic receptor antagonists (see ADVERSE REACTIONS).
Immune Hypersensitivity Immediate hypersensitivity reactions, including urticaria, angioedema (including swelling of the lips, tongue or throat), rash, bronchospasm, anaphylaxis, or itching may occur after administration of SPIRIVA RESPIMAT.
If such a reaction occurs, therapy with SPIRIVA RESPIMAT should be stopped at once and alternative treatments should be considered. Given the similar structural formula of atropine to tiotropium, patients with a history of hypersensitivity Spiriva® Respimat® Product Monograph Page 6 of 41 reactions to atropine or its derivatives should be closely monitored for similar hypersensitivity reactions to SPIRIVA RESPIMAT.
Ophthalmologic Worsening of Narrow-Angle Glaucoma (see WARNINGS AND PRECAUTIONS, Anticholinergic Effects). Renal As with all predominantly renally excreted drugs, SPIRIVA RESPIMAT should be used only if the expected benefit outweighs the potential risk in patients with moderate to severe renal impairment (creatinine clearance of 50 ml/min).
These patients should be monitored closely for potential adverse drug reactions. Worsening of Urinary Retention (see WARNINGS AND PRECAUTIONS, Anticholinergic Effects). 0011 mg benzalkonium chloride in each actuation. Benzalkonium chloride may cause wheezing and breathing difficulties.
Patients with asthma are at an increased risk for these adverse events. Paradoxical bronchospasm Inhaled medicines may cause inhalation-induced bronchospasm. If this occurs, treatment with SPIRIVA RESPIMAT should be discontinued immediately.
Special Populations Pregnant Women:
There is a limited amount of data from the use of tiotropium in pregnant women. Pre-clinical studies do not indicate direct or indirect harmful […]